NasdaqGS:ADPTLife Sciences
Adaptive Biotechnologies (ADPT) Stock Looks Fair On Cash Flow Yet Rich On Sales
Adaptive Biotechnologies stock has seen very strong share price gains over the past few years, yet valuation checks now suggest it is no longer an obvious bargain. The intrinsic value estimate from a Discounted Cash Flow (DCF) model is close to the current price, while market multiples appear expensive.
Adaptive Biotechnologies has returned about 305.9% over the past 3 years, which puts extra focus on whether recent enthusiasm already reflects much of the potential.
Expectations for future...